科研製薬の業績推移
(単位:百万円)
|
売上高 |
営業利益 |
経常利益 |
純利益 |
売上原価 |
売上総利益 |
株主資本 |
総負債 |
総資産 |
現金及び現金同等物 |
流動市場性有価証券 |
流動資産 |
流動負債 |
利益剰余金 |
営業利益率 |
経常利益率 |
当期利益率 |
自己資本比率 |
営業キャッシュフロー |
投資キャッシュフロー |
財務キャッシュフロー |
営業キャッシュフローマージン |
フリーキャッシュフロー |
ROE |
ROA |
一株あたり利益 |
希薄化後一株あたり利益 |
従業員数 |
2024年3月
|
72,044
|
9,513
|
9,951
|
8,025
|
33,505
|
38,539
|
143,755
|
27,868
|
171,623
|
50,625
|
|
106,974
|
19,024
|
128,506
|
13.2%
|
13.81%
|
11.14%
|
83.76%
|
2,577
|
-5,854
|
-5,658
|
3.58%
|
-3,277
|
5.72%
|
4.75%
|
0.00021267
|
0.00021267
|
1135人
|
2023年3月
|
72,984
|
7,998
|
8,727
|
5,440
|
33,428
|
39,556
|
136,836
|
29,492
|
166,328
|
59,561
|
|
109,903
|
20,838
|
126,135
|
10.96%
|
11.96%
|
7.45%
|
82.27%
|
9,253
|
-2,627
|
-6,990
|
12.68%
|
6,626
|
3.95%
|
3.28%
|
0.0001448
|
0.0001448
|
1130人
|
2022年3月
|
76,034
|
17,064
|
17,542
|
9,549
|
34,458
|
41,576
|
138,325
|
26,856
|
165,181
|
61,025
|
|
110,613
|
19,049
|
126,347
|
22.44%
|
23.07%
|
12.56%
|
83.74%
|
13,336
|
-7,888
|
-8,129
|
17.54%
|
5,448
|
6.96%
|
5.81%
|
0.00025143
|
0.00025143
|
1164人
|
2021年3月
|
74,979
|
17,788
|
18,222
|
13,405
|
34,073
|
40,906
|
136,257
|
27,075
|
163,332
|
63,706
|
|
113,662
|
21,276
|
122,462
|
23.72%
|
24.3%
|
17.88%
|
83.42%
|
14,380
|
-1,644
|
-8,752
|
19.18%
|
12,736
|
10.13%
|
8.35%
|
0.00034737
|
0.00034737
|
1215人
|
2020年3月
|
89,232
|
26,512
|
26,946
|
19,370
|
38,753
|
50,479
|
128,468
|
29,407
|
157,875
|
59,722
|
|
108,336
|
21,655
|
114,869
|
29.71%
|
30.2%
|
21.71%
|
81.37%
|
27,468
|
-2,528
|
-10,173
|
30.78%
|
24,940
|
15.52%
|
12.34%
|
0.00049489
|
0.00049489
|
1268人
|
2019年3月
|
94,165
|
24,592
|
24,972
|
17,775
|
40,366
|
53,799
|
121,131
|
34,854
|
155,985
|
46,956
|
|
103,731
|
27,580
|
109,057
|
26.12%
|
26.52%
|
18.88%
|
77.66%
|
21,129
|
-5,744
|
-9,524
|
22.44%
|
15,385
|
15.13%
|
11.53%
|
0.00044578
|
0.00044578
|
1341人
|
2018年3月
|
98,430
|
27,496
|
27,854
|
19,043
|
42,405
|
56,025
|
113,874
|
38,543
|
152,417
|
45,095
|
|
103,859
|
31,401
|
97,284
|
27.93%
|
28.3%
|
19.35%
|
74.71%
|
21,703
|
-3,245
|
-9,530
|
22.05%
|
18,458
|
17.59%
|
13.25%
|
0.00047054
|
0.00047054
|
1389人
|
2017年3月
|
101,479
|
30,707
|
30,981
|
22,017
|
44,539
|
56,940
|
102,655
|
32,405
|
135,060
|
33,867
|
|
90,494
|
24,020
|
84,331
|
30.26%
|
30.53%
|
21.7%
|
76.01%
|
15,327
|
-3,503
|
-9,800
|
15.1%
|
11,824
|
22.87%
|
16.43%
|
0.0005367
|
0.0005367
|
1405人
|
2016年3月
|
109,730
|
35,146
|
35,365
|
21,143
|
47,580
|
62,150
|
89,875
|
43,116
|
132,991
|
29,845
|
|
88,991
|
33,861
|
68,609
|
32.03%
|
32.23%
|
19.27%
|
67.58%
|
27,067
|
-4,105
|
-5,984
|
24.67%
|
22,962
|
25.32%
|
17.04%
|
0.00051054
|
0.00051054
|
1451人
|
2015年3月
|
93,889
|
20,631
|
20,394
|
12,122
|
44,760
|
49,129
|
77,100
|
38,035
|
115,135
|
10,553
|
|
69,016
|
30,369
|
52,932
|
21.97%
|
21.72%
|
12.91%
|
66.96%
|
14,737
|
473
|
-7,900
|
15.7%
|
15,210
|
16.7%
|
10.94%
|
0.0002909
|
0.0002909
|
1503人
|
2014年3月
|
88,946
|
15,872
|
15,521
|
9,735
|
45,169
|
43,777
|
68,096
|
38,369
|
106,465
|
9,644
|
|
58,501
|
28,056
|
49,789
|
17.84%
|
17.45%
|
10.94%
|
63.96%
|
13,663
|
-2,135
|
-10,992
|
15.36%
|
11,528
|
14.46%
|
9.04%
|
0.00022827
|
0.00022827
|
1540人
|
2013年3月
|
87,054
|
14,611
|
14,250
|
8,991
|
44,961
|
42,093
|
66,578
|
42,333
|
108,911
|
9,710
|
|
61,983
|
35,232
|
43,997
|
16.78%
|
16.37%
|
10.33%
|
61.13%
|
11,729
|
-6,792
|
-5,867
|
13.47%
|
4,937
|
13.98%
|
8.4%
|
0.00020661
|
0.00020661
|
1666人
|
2012年3月
|
87,997
|
|
14,803
|
8,282
|
|
|
62,071
|
43,037
|
105,108
|
17,851
|
|
|
|
|
0.0%
|
16.82%
|
9.41%
|
59.05%
|
10,285
|
-2,563
|
-6,904
|
11.69%
|
7,722
|
|
|
0.00018493
|
0.00018493
|
1668人
|
2011年3月
|
86,428
|
|
13,713
|
8,213
|
|
|
|
|
|
|
|
|
|
|
0.0%
|
15.87%
|
9.5%
|
|
|
|
|
|
|
|
|
0.00008787
|
0.00008787
|
1679人
|
2010年3月
|
85,022
|
|
11,308
|
6,734
|
|
|
|
|
|
|
|
|
|
|
0.0%
|
13.3%
|
7.92%
|
|
|
|
|
|
|
|
|
0.00006879
|
0.00006879
|
1687人
|